76,106 Illumina, Inc. $ILMN Shares Sold by Howard Capital Management LLC

Key Points

• Howard Capital Management cut its Illumina stake by 43.2%, selling 76,106 shares and retaining 100,204 shares worth approximately $27.4 million. Institutional investors and hedge funds collectively own 89.42% of the company.
• Illumina insiders sold 2.06 million shares worth $436.5 million over the past 90 days, including Director Keith Meister’s sale of 457,858 shares for $91.6 million.
• Illumina reported quarterly earnings of $1.31 per share and $1.16 billion in revenue, exceeding analyst expectations. Despite several analyst upgrades, the stock carries a consensus “Hold” rating with an average price target of $225.94.

Howard Capital Management LLC trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 43.2% in the third quarter, according to its most recent filing with the SEC. The firm owned 100,204 shares of the life sciences company's stock after selling 76,106 shares during the period. Howard Capital Management LLC owned approximately 0.07% of Illumina worth $27,424,000 as of its most recent filing with the SEC.

A number of other institutional investors also recently added to or reduced their stakes in ILMN. BlackRock Inc. bought a new position in Illumina in the second quarter valued at approximately $3,374,423,000. Plato Investment Management Ltd acquired a new stake in Illumina during the 2nd quarter worth $948,000. Mitsubishi UFJ Asset Management Co. Ltd. acquired a new stake in Illumina during the 2nd quarter worth $30,501,000. Edmond DE Rothschild Holding S.A. bought a new stake in shares of Illumina during the 2nd quarter valued at $129,792,000. Finally, OVERSEA CHINESE BANKING Corp Ltd bought a new stake in shares of Illumina during the 2nd quarter valued at $6,711,000. 89.42% of the stock is owned by institutional investors and hedge funds.

Insider Buying and Selling at Illumina

In other news, Director Keith Meister sold 457,858 shares of Illumina stock in a transaction on Tuesday, August 4th. The stock was sold at an average price of $200.10, for a total transaction of $91,617,385.80. Following the completion of the sale, the director owned 2,372,694 shares of the company's stock, valued at approximately $474,776,069.40. This trade represents a 16.18% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Insiders sold a total of 2,061,850 shares of company stock worth $436,479,102 in the last 90 days. 2.90% of the stock is currently owned by company insiders.

Illumina Stock Down 2.0%

Shares of ILMN traded down $5.39 during midday trading on Friday, hitting $262.54. The stock had a trading volume of 2,488,994 shares, compared to its average volume of 4,371,835. The firm has a market cap of $39.64 billion, a price-to-earnings ratio of 48.98, a price-to-earnings-growth ratio of 3.79 and a beta of 1.41. The company has a 50 day simple moving average of $234.53 and a two-hundred day simple moving average of $186.01. Illumina, Inc. has a twelve month low of $94.00 and a twelve month high of $309.35. The company has a debt-to-equity ratio of 0.53, a current ratio of 1.80 and a quick ratio of 1.40.

Illumina (NASDAQ:ILMN - Get Free Report) last announced its quarterly earnings data on Thursday, July 30th. The life sciences company reported $1.31 EPS for the quarter, topping analysts' consensus estimates of $1.23 by $0.08. The business had revenue of $1.16 billion for the quarter, compared to analyst estimates of $1.13 billion. Illumina had a net margin of 18.36% and a return on equity of 29.84%. The firm's revenue for the quarter was up 9.4% on a year-over-year basis. During the same quarter in the previous year, the firm posted $1.19 earnings per share. Illumina has set its FY 2026 guidance at 5.300-5.400 EPS. On average, analysts anticipate that Illumina, Inc. will post 5.36 EPS for the current year.

Wall Street Analyst Weigh In

A number of research analysts recently issued reports on ILMN shares. Weiss Ratings restated a "hold (c)" rating on shares of Illumina in a report on Monday, August 31st. Piper Sandler increased their target price on shares of Illumina from $225.00 to $305.00 and gave the stock an "overweight" rating in a report on Monday, September 28th. Leerink Partners lifted their price target on shares of Illumina from $220.00 to $300.00 and gave the stock an "outperform" rating in a research report on Tuesday, September 29th. Argus boosted their price target on shares of Illumina from $180.00 to $235.00 and gave the company a "buy" rating in a report on Thursday, September 3rd. Finally, Wall Street Zen upgraded shares of Illumina from a "hold" rating to a "buy" rating in a research report on Sunday, October 11th. Ten analysts have rated the stock with a Buy rating, six have assigned a Hold rating and two have assigned a Sell rating to the stock. According to MarketBeat.com, Illumina presently has a consensus rating of "Hold" and an average price target of $225.94.

About Illumina

Illumina, Inc develops and manufactures technologies used to analyze genetic variation and biological function. Its products are primarily based on next-generation sequencing, a method that enables researchers and clinicians to read DNA and RNA for applications including genomic research, disease studies, drug development and clinical testing.

The company offers sequencing instruments, consumables such as reagent kits and flow cells, and related software and informatics solutions. Illumina also provides services and support designed to help customers prepare samples, run sequencing workflows, interpret genomic data and integrate results into research or clinical operations.

Founded in 1998 and headquartered in San Diego, California, Illumina serves customers worldwide, including academic and government research institutions, pharmaceutical and biotechnology companies, hospitals, clinical laboratories and other healthcare organizations.

Want to see what other hedge funds are holding ILMN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Illumina, Inc. (NASDAQ:ILMN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.